BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China flag China · Delayed Price · Currency is CNY
53.39
+1.49 (2.87%)
At close: Oct 24, 2025
2.87%
Market Cap22.57B
Revenue (ttm)1.16B
Net Income (ttm)99.98M
Shares Out422.74M
EPS (ttm)0.24
PE Ratio225.53
Forward PE86.11
Dividend0.10 (0.18%)
Ex-Dividend DateJun 23, 2025
Volume9,301,780
Average Volume14,015,073
Open52.30
Previous Close51.90
Day's Range52.01 - 53.86
52-Week Range28.45 - 122.59
Beta0.08
RSI27.34
Earnings DateOct 31, 2025

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, inc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 1,151
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688166
Full Company Profile

Financial Performance

In 2024, SHA:688166's revenue was 1.28 billion, an increase of 8.74% compared to the previous year's 1.18 billion. Earnings were 189.17 million, a decrease of -6.57%.

Financial Statements

News

There is no news available yet.